drugset / Trial / NCT01486368
A Phase II Study of PF-03446962 in Patients With Advanced Malignant Pleural Mesothelioma
NaSingle-groupOpen-labelTreatment
Summary
This is a non-randomized open label multicentre Phase II trial to evaluate the response rate of PF03446962 in patients with advanced malignant pleural mesothelioma who have been previously treated with cytotoxic chemotherapy.
Timeline
- Start
- 2012-06-26
- Primary completion
- 2014-04-27
- Completion
- 2015-02-13
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | ASCRINVACUMAB | Monoclonal antibody | — | Intravenous |